Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA 510(k)

Comprehensive Segmental Revision System (SRS)

K-Number: K173411 · 2018-02-08

Decision Date2018-02-08
Product CodePHX
Advisory CommitteeOR
DecisionSubstantially Equivalent

Device Summary

Comprehensive Segmental Revision System (SRS) is a medical device manufactured by Biomet Manufacturing Corp. It received FDA 510(k) clearance on 2018-02-08 under approval number K173411. The device is classified under product code PHX. It was reviewed by the OR advisory panel. FDA Decision: Substantially Equivalent.

Frequently Asked Questions

What is the Comprehensive Segmental Revision System (SRS)?

Comprehensive Segmental Revision System (SRS) is a medical device that received FDA 510(k) clearance on 2018-02-08. It is manufactured by Biomet Manufacturing Corp. The 510(k) number is K173411.

When was Comprehensive Segmental Revision System (SRS) approved by the FDA?

Comprehensive Segmental Revision System (SRS) received FDA 510(k) clearance on 2018-02-08, under approval number K173411.

What company makes Comprehensive Segmental Revision System (SRS)?

Comprehensive Segmental Revision System (SRS) is manufactured by Biomet Manufacturing Corp.

What is the FDA product code for Comprehensive Segmental Revision System (SRS)?

The FDA product code for Comprehensive Segmental Revision System (SRS) is PHX.

Related Clinical Trials

Related PubMed Literature

Other Devices by Biomet Manufacturing Corp

View all 16 devices →

Related Devices (Code: PHX)

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.